Michael David Smith - 26 May 2021 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
Senior VP, Development
Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Issuer symbol
KALV
Transactions as of
26 May 2021
Net transactions value
$0
Form type
4
Filing time
28 May 2021, 17:29:39 UTC
Next filing
03 Jun 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Employee Stock Option (Right to Buy) Award $0 +35,000 $0.000000 35,000 26 May 2021 Common Stock 35,000 $25.95 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests over a 4 year period: 1/48th on June 26, 2021, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date.